针对癌症治疗的基因组脱甲基酶的当前进展和未来方向
June-Ha Shin1, Hye-Been Yoo1, Jae-Seok Roe1
1Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea.
Molecules and cells
|February 12, 2025
概括
基因组 lysine 脱甲基酶 (KDMs) 是癌症中的关键表观遗传调节剂. 用小分子准KDM为量身定制的癌症治疗提供了有前途的精确瘤学策略.
科学领域:
- 表观遗传学和分子生物学
- 癌症生物学 癌症生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 表观遗传调节器 (写字器,擦拭器,阅读器) 通过组织蛋白修饰来控制基因表达.
- 这些调节剂在癌症发病和进展中起着关键作用.
- 针对表观遗传酶的新兴临床策略在癌症治疗中表现有前途.
研究的目的:
- 审查基因组 lysine 脱甲基酶 (KDMs) 与癌症之间的功能关系.
- 讨论针对KDM的小分子化合物的开发和应用.
- 突出KDM在精密瘤学的潜力.
主要方法:
- 文献综述专注于癌症中的KDM.
- 对小分子KDM抑制剂的研究分析.
- 综合目前对各种癌症类型中KDM功能的理解.
主要成果:
- KDMs在基因转录中表现出不同的作用,影响癌症的发展.
- 癌细胞KDM的活性和结果取决于甲基化素的位置和癌细胞的环境.
- 小分子KDM抑制剂正在开发用于治疗应用.
结论:
- 鉴于其特定背景的作用,KDM是精密瘤学的有价值的目标.
- 针对KDM提供了开发新,量身定制的癌症治疗的机会.
- 对KDM抑制剂的进一步研究可能会导致癌症治疗的重大进展.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Histone Modification
3.4K
3.4K
Histone Variants at the Centromere
4.3K
Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
4.3K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Spreading of Chromatin Modifications
8.2K
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
Writers
The writer...
8.2K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K


